Study on the Mechanism of Immunoglobulin-Based Targeted Therapy in Tumor Immune Escape

Jiayi Liu

Jining Confucius High School, Jining 272000, China

Abstract. This article aims to explore the targeted therapy strategy based on immunoglobulin and its application and prospect in tumor immunotherapy. By reviewing the basic structure and classification of immunoglobulin, its role in immune system and its close relationship with tumor immunity, this article reveals the importance of immunoglobulin as a key molecule in immunotherapy. Furthermore, the principle of tumor immunotherapy with targeted immunoglobulin is expounded in detail, including specific methods such as immune checkpoint inhibitor therapy, antibody-coupled drug therapy and chimeric antigen receptor T cell therapy. At the same time, this article lists a variety of clinical application cases of cancer treatment, such as breast cancer, lymphoma and lung cancer, which shows the remarkable curative effect and wide application prospect of targeted therapy. Through the analysis of clinical data and the assessment of treatment effect, this article confirmed the remarkable effect of targeted therapy based on immunoglobulin in improving patient survival rate, tumor remission rate and quality of life. However, the follow-up still needs to be explored and optimized to achieve better therapeutic effects.

Keywords: Immunoglobulin, targeted therapy, tumor immunity, clinical application, treatment effect.

1. Introduction

In the contemporary medical landscape, cancer stands as a leading global cause of mortality, with its treatment and research continually at the forefront of scientific inquiry [1]. As the biological intricacies of tumors are delved into, it's increasingly recognized that tumorigenesis transcends mere unregulated cell growth, encompassing a complex immune evasion mechanism [2]. This immune escape by tumor cells, wherein they circumvent immune system surveillance and elimination through various means, plays a pivotal role in tumor initiation and progression [3]. Recently, immunoglobulin-targeted therapy has emerged as a focal point in tumor immunotherapy due to its capacity for precise tumor cell targeting and minimized harm to healthy tissues [4]. The aim of this research is to investigate the impact of immunoglobulin-based targeted therapy on tumor immune escape mechanisms, offering novel insights and approaches for cancer management.

The main purpose of this study is to further reveal the key mechanism of immunoglobulin in tumor immune escape by analyzing its biological characteristics and its role in immune system. By comparing the effects of different immunoglobulin targeted therapy strategies, this article evaluates their potential in inhibiting tumor growth and promoting tumor cell apoptosis, and provides theoretical basis for developing more effective tumor immunotherapy drugs. The significance of this study is that it not only helps to deepen the understanding of tumor immune escape mechanism, but also may bring breakthrough progress in the field of tumor immunotherapy and bring new hope to tumor patients.

2. Biological Characteristics of Immunoglobulin

2.1 Basic Structure of Immunoglobulin

Immunoglobulin, an immune-functional protein, is synthesized by plasma cells upon antigenic stimulation [5]. It is ubiquitous in serum, tissue fluids, and exocrine secretions, serving as crucial effector molecules in humoral immunity. Structurally, immunoglobulin comprises two identical heavy (H) chains and two identical light (L) chains, interlinked by disulfide bonds, forming a Y-shape

[6]. Each chain harbors a variable region that dictates the antibody's specificity, or antigen recognition capacity, and a constant region associated with its biological activities.

Based on heavy chain types and structural variations, immunoglobulins are classified into five distinct classes: IgG, IgM, IgA, IgD, and IgE. These classes exhibit differences in distribution, functional roles, and antigen-binding properties [7]. For example, IgG is the immunoglobulin with the highest content in serum, which participates in the secondary immune response and exerts its immune effect mainly by activating the complement system; IgM is the earliest antibody produced in the initial immune response, which mainly exists in the blood and has strong ability of sterilization, bacteriolysis and activation of complement.

2.2 The Role of Immunoglobulin in Immune System

Immunoglobulin is a key player in the immune system, functioning by specifically recognizing and binding to antigens. This interaction forms antigen-antibody complexes, which hinder the antigens' ability to further invade the body [8]. This process serves multiple purposes: it can directly neutralize the toxicity of pathogens like viruses and bacteria, and it bolsters the body's immunity. By promoting phagocytosis-the engulfing and digestion of foreign particles by phagocytes—and activating the complement system, immunoglobulins facilitate the removal of harmful substances. Additionally, they regulate the immune response, ensuring it is neither too aggressive nor too weak. Figure 1 illustrates these functions of immunoglobulin.



Figure 1. Functions of immunoglobulin

2.3 Relationship between Immunoglobulin and Tumor Immunity

Immunoglobulin occupies a pivotal role in the field of tumor immunity. Tumor cells, being abnormal growths, often express unique antigens that can be recognized by the body's immune system. This recognition triggers an immune reaction aimed at eliminating the tumor cells. As a central component of this immune response, immunoglobulin plays a crucial role by specifically binding to these tumor-associated antigens. This binding facilitates the targeting and elimination of the tumor cells by the immune system.

However, tumor cells are adept at evading the immune system's detection and removal mechanisms. One of the key strategies they employ is the modulation of immunoglobulin production and functionality. By interfering with the normal production and activity of immunoglobulins, tumor cells can reduce the effectiveness of the immune response against them.

Understanding the intricate interplay between immunoglobulins and tumor cells has opened up new avenues for cancer treatment. By fine-tuning the production and activity of immunoglobulins, researchers and clinicians aim to enhance the body's anti-tumor immune response. This can be achieved through various means, such as developing immunotherapies that stimulate the production

of specific immunoglobulins targeting tumor antigens, or using monoclonal antibodies—laboratory-produced immunoglobulins-to directly target and eliminate tumor cells.

3. Targeted Therapy Strategy based on Immunoglobulin

3.1 The Principle of Tumor Immunotherapy Targeting Immunoglobulin

The core principle of tumor immunotherapy that centers on immunoglobulin is rooted in its critical role within tumor immunity and its direct interaction with tumor cells. Immunoglobulin, as an integral part of the body's immune defense mechanism, exhibits a remarkable ability to accurately recognize and bind to specific antigens that are expressed on the surface of tumor cells. This precise targeting is the cornerstone of immunoglobulin-based immunotherapies.

When immunoglobulin binds to these tumor-specific antigens, it triggers a series of immune reactions. One of the key consequences is the activation of T-cells, which are essential for mounting an effective immune response against cancer. T-cells, upon activation, can directly attack and eliminate tumor cells, or they can orchestrate a broader immune response by recruiting other immune cells to the site of the tumor.

Furthermore, immunoglobulin's interaction with tumor cells can enhance the efficacy of immune checkpoint inhibitors. Immune checkpoint inhibitors are a class of drugs that work by blocking certain proteins on immune cells, thereby releasing the brakes on the immune system and allowing it to more effectively attack cancer cells. By modulating this intricate process, immunoglobulin-based therapies can restore or amplify the immune system's ability to detect and combat tumor cells.

Ultimately, the goal of tumor immunotherapy that leverages immunoglobulin is to harness the power of the immune system to treat cancer effectively. By precisely targeting tumor cells and initiating a robust immune response, immunoglobulin-based therapies offer a promising approach to cancer treatment that is both targeted and potent.

3.2 Specific Targeted Therapy Methods

(1) Immunocheckpoint Inhibitor Approach:

Principle: Tumor cells evade immune assault by activating inhibitory T-cell signals. Immunocheckpoint inhibitors counteract these signals, thereby augmenting the immune system's antitumor lethality.

Illustration: Targeting the programmed death receptor 1 (PD-1) and its ligand (PD-L1) has exhibited promising clinical outcomes across multiple cancer types. Furthermore, inhibitors targeting additional immune checkpoints, such as CTLA-4 and LAG-3, are in developmental stages.

(2) Antibody-Drug Conjugate (ADC) Strategy:

Principle: ADCs are composed of immunoglobulins with high specificity, linked to cytotoxic agents. They precisely identify and bind to tumor cell surface antigens, facilitating direct delivery of cytotoxic drugs into tumor cells for targeted therapy.

Case Study: Tratuzumab-Metazine conjugate (T-DM1) is employed in the treatment of HER2-overexpressing breast cancer.

(3) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy:

Principle: Utilizing genetic engineering, the variable region gene of immunoglobulins that recognize tumor cell surface antigens is incorporated into T cells, enabling them to specifically identify and eliminate tumor cells.

Instance: CD19 CAR-T cell therapy serves as a treatment for relapsed or refractory B-cell acute lymphoblastic leukemia.

3.3 Effect and Mechanism of Targeted Therapy

Tumor immunotherapy with targeted immunoglobulin has shown good efficacy in the treatment of many cancers. Its therapeutic effect is mainly reflected in the following aspects:

(1) Improving the tumor remission rate: By specifically recognizing and binding the antigen on the surface of tumor cells, targeted drugs can accurately attack tumor cells, thus improving the tumor remission rate.

(2) Prolonging the survival time: For some patients who are insensitive to traditional treatment or have developed drug resistance, targeted immunotherapy can significantly prolong their survival time.

(3) Improving the quality of life: Compared with traditional chemotherapy and radiotherapy, targeted immunotherapy has relatively few side effects, which can alleviate the pain of patients and improve the quality of life.

Targeted therapy mechanism mainly includes:

(1) Restore the anti-tumor ability of the immune system: Targeted drugs can restore or enhance the immune system's ability to recognize and attack tumor cells by inhibiting immune checkpoint signals or enhancing the function of immune cells.

(2) Direct killing of tumor cells: For example, antibody-coupled drugs and CAR-T cell therapy can directly deliver cytotoxic drugs into tumor cells or specifically identify and attack tumor cells, thus achieving direct killing effect.

(3) Regulating tumor microenvironment: Targeted drugs can also regulate tumor microenvironment, such as inhibiting tumor angiogenesis and regulating the function of tumor-related macrophages, so as to provide better conditions for immune cells to play their roles.

4. Clinical Application of Targeted Therapy based on Immunoglobulin

4.1 Clinical Application Cases

Immunoglobulin-centric targeted therapies have demonstrated impressive results across numerous clinical domains, notably in cancer management. Below are illustrative examples of their clinical applications:

Breast Cancer Management: Trastuzumab, a targeted agent for HER2-positive breast cancer, operates by binding to the HER2 receptor, thereby inhibiting tumor growth and promoting cancer cell apoptosis. Its widespread clinical use has notably enhanced survival rates and prognosis for patients with this subtype of breast cancer.

Lymphoma Therapy: Rituximab, a chimeric IgG1κ monoclonal antibody targeting the CD20 antigen, is employed in the treatment of various B-cell malignancies, including non-Hodgkin's lymphoma. It specifically binds to CD20 on B-cell surfaces, triggering apoptosis and bolstering the immune system's antitumor capabilities.

Lung Cancer Intervention: Nimotuzumab, a targeted drug aimed at the epidermal growth factor receptor (EGFR), is utilized for solid tumors like non-small cell lung cancer. By specifically binding to EGFR, it suppresses tumor cell multiplication and angiogenesis, effectively managing tumor progression.

4.2 Therapeutic Effect Assessment

The assessment of targeted therapy based on immunoglobulin mainly relies on clinical trial data and patient prognosis. By comparing the survival rate, tumor response rate, quality of life, and other indicators between the treatment group and the control group, the efficacy of targeted therapy can be objectively evaluated (as shown in Table 1). At the same time, attention should be paid to the side effects and safety of treatment to ensure that patients can tolerate and achieve the best therapeutic effect during the treatment process.

In clinical practice, targeted therapy leveraging immunoglobulin has demonstrated impressive results across various cancer types. Studies have consistently shown that these treatments can boost patient survival rates and tumor remission rates. Beyond these quantitative improvements, immunoglobulin-based therapies also positively impact patients' quality of life. They often lead to fewer and less severe side effects compared to traditional cancer treatments, allowing patients to maintain a higher level of daily functioning and overall well-being. This combination of enhanced

efficacy and reduced toxicity makes immunoglobulin-based targeted therapies a valuable addition to the arsenal of cancer treatment options.

Table 1. Assessment of Targeted Therapy Efficacy Based on Immunoglobulin

Assessment Index	Treatment Group	Control Group	Remarks
Overall Survival Rate (OS)	Increased by 20%	Baseline level	The 5-year survival rate in the control group was 50%, while it increased to 60% in the treatment group.
Progression-Free Survival (PFS)	Extended by 3 months	Baseline level	In the control group, the median Progression-Free Survival (PFS) was 6 months; however, this increased to 9 months in the treatment group.
Objective Response Rate (ORR)	50%	30%	The Objective Response Rate (ORR) encompasses both complete and partial responses among patients.
Disease Control Rate (DCR)	80%	60%	The Disease Control Rate (DCR) includes patients exhibiting complete response, partial response, or stable disease.
Quality of Life Score (QOL)	Increased by 15 points	Baseline level	Using a quality of life (QOL) scoring scale, the average QOL score of patients in the treatment group improved by 15 points.
Incidence of Grade 3-4 Adverse Events	15%	20%	Grade 3-4 adverse events represent severe adverse reactions, and a lower incidence rate indicates better treatment safety.

5. Conclusion

This study mainly discusses the targeted therapy strategy based on immunoglobulin and its clinical application and prospect. By reviewing the basic structure and classification of immunoglobulin, its role in immune system and its relationship with tumor immunity, this article deeply understands the principles and methods of targeted therapy. At the same time, by introducing clinical application cases and assessment of treatment effect, this article shows the remarkable curative effect and broad application prospect of targeted therapy in cancer treatment.

The significance of this study lies in its thorough analysis of the importance and potential of targeted therapy strategies grounded in immunoglobulin, offering fresh perspectives and methodologies for cancer treatment. By consistently refining and enhancing targeted drugs, and thereby improving treatment safety and efficacy, superior treatment options and an enhanced quality of life can be provided to patients.

In anticipation of future advancements, with the relentless progress of science and technology and a deeper comprehension of tumor immune mechanisms, targeted therapy based on immunoglobulin is poised to assume a more prominent role in cancer treatment. Concurrently, there is a need to continually explore novel therapeutic targets and approaches, fostering the advancement and widespread adoption of personalized treatment, ultimately leading to improved therapeutic outcomes and higher survival rates for cancer patients.

References

[1] Xu L, Che S, Hou J Y. PPARγ agonist inhibits c-Myc-mediated colorectal cancer tumor immune escape[J]. Journal of cellular biochemistry. 2023, 124(8):1145-1154.

[2] Dong G, Wang Q, Wen M, et al. DDX18 drives tumor immune escape through transcription-activated STAT1 expression in pancreatic cancer[J]. Oncogene, 2023, 42(40): 3000-3014.

[3] Li Z, Wang J, Zhang X, et al. Proinflammatory S100A8 Induces PD-L1 Expression in Macrophages, Mediating Tumor Immune Escape[J]. The Journal of Immunology, 2020, 204(9):2589-2599.

[4] Jiao W, Feng Y, Liang C, et al. Reprogramming the tumor immune microenvironment via nanomaterial-mediated dynamic therapy[J]. Nano Research, 2023, 16(12):13100-13112.

[5] Ren P, Yu X, Yue Y X C. Dietary supplementation with astaxanthin enhances anti-tumor immune response and aids the enhancement of molecularly targeted therapy for hepatocellular carcinoma[J]. Food & Function, 2023, 14(18):8309-8320.

[6] Li X, He X, Lin B, et al. Quercetin Limits Tumor Immune Escape through PDK1/CD47 Axis in Melanoma[J]. The American Journal of Chinese Medicine, 2024, 52(02):541-563.

[7] Zhao L, Pei R, Ding Y, et al. LOXL4 Shuttled by Tumor Cells–derived Extracellular Vesicles Promotes Immune Escape in Hepatocellular Carcinoma by Activating the STAT1/PD-L1 Axis[J]. Journal of Immunotherapy, 2023, 47(2):64-76.

[8] Li X, Xu W. CD147-mediated reprogrammed glycolytic metabolism potentially induces immune escape in the tumor microenvironment[J]. Oncology reports, 2019, 41(5): 2945-2956.